Advertisement

Pharmakokinetik von Isosorbiddinitrat während einer Toleranzentwicklung

  • Ho-Leung Fung
Conference paper

Zusammenfassung

Eine der Kernfragen dieses Symposions lautet: „Führt die chronische Anwendung organischer Nitrate im klinischen Gebrauch zu einer Toleranz bezüglich ihrer günstigen Wirkungen?“. Die einzelnen Kapitel befassen sich mit klinischen Beweisen für und wider diese Hypothese. Gegenstand dieses Gespräches ist auch, zu klären, ob die chronische Nitratgabe Veränderungen der Pharmakokinetik bzw. der Schnelligkeit und des Ausmaßes der Absorption, Verteilung und Elimination des Arzneistoffes bewirkt und zu ermitteln, ob diese pharmakokinetischen Veränderungen, falls vorhanden, mit den verschiedenen Mechanismen, die zur Erklärung einer Nitrattoleranz angeführt werden könnten, vereinbar sind.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Thadani U, Fung H-L, Darke AC, and Parker JO, “Oral Isosorbide Dinitrate in the Treatment of Angina Pectoris. Dose Response Relationship and Duration of Action During Acute Therapy”, Circulation 62: 491–502 (1980).PubMedCrossRefGoogle Scholar
  2. 2.
    Fung H-L, McNiff EF, Ruggirello D, Darke A, Thadani U, and Parker JO, “Kinetics of Isosorbide Dinitrate and Relationships to Pharmacological Effects”, Brit J Clin Pharmacol 11: 579–590 (1981).CrossRefGoogle Scholar
  3. 3.
    Thadani U, Fung H-L, Darke AC, and Parker JO, “Oral Isosorbide Dinitrate in Angina Pectoris. Comparison of Duration of Action and Dose Response Relationship during Acute and Sustained Therapy”, Am J Cardiol, in press.Google Scholar
  4. 4.
    Thadani U, Manyari D, Parker JO, and Fung H-L, “Tolerance to the Circulatory Effects of Oral Isosorbide Dinitrate. Rate of Development and Cross Tolerance to Glyceryl Trinitrate”, Circulation 61: 526–535 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    Armstrong-Moffat JA, Marks GS, Watts DG, and Armstrong PW, “Tolerance to the Hemodynamic Effects of Nitroglycerin”, Abstract of the Scientific Program, the 34th Annual Meeting of the Canadian Cardiovascular Society, October 28–31, 1981, p. 111.Google Scholar
  6. 6.
    Fung H-L, and Kamiya A, “Disposition of Nitroglycerin in Rat Plasma and Selected Blood Vessels”, Abstracts of the Eighth International Congress of Pharmacology, July 19–24, 1981, Tokyo, p. 552.Google Scholar
  7. 7.
    Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, and Gruetter CA, “Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside, and Nitric Oxide: Evidence for the Involvement of S-Nitrosothiols as Active Intermediates”, J Pharmacol Exp Ther 218: 739–749 (1981).PubMedGoogle Scholar
  8. 8.
    Needleman P, Jakschik B, and Johnson EM, “Sulfhydryl Requirement for Relaxation of Vascular Smooth Muscle”, J Pharmacol Exp Ther 187: 324–331 (1973).PubMedGoogle Scholar
  9. 9.
    Keith RA, and Burkman AM, “In Vitro Induction of Nitroglycerin (NTG) Tolerance in Vascular Tissue at pH 7.4 and 9.0 Occurs Prior to the Decrease in Sulfhydryl (SH) Content”, Fed Proc (abstract) 40: 729 (1981).Google Scholar
  10. 10.
    Morrison RA, and Fung H-L, unpublished data.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • Ho-Leung Fung
    • 1
  1. 1.Department of Pharmaceutics School of PharmacyState University of New York at BuffaloAmherstUSA

Personalised recommendations